{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
city
~15 mi. (Kirkland, Canada, +23 more cities)
facility
Merck Canada
condition
Prostate Adenocarcinoma, +1 more condition
drug
abiraterone, +9 more drugs
drug type
chemotherapy, +3 more types
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
city
~21 mi. (Montréal, Canada, +128 more cities)
facility
Hopital Maisonneuve-Rosemont
drug
bortezomib, +5 more drugs
drug type
cellular therapy, +4 more types
A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
city
~21 mi. (Montréal, Canada, +226 more cities)
facility
McGill University Health Centre
biomarker
EGFR Exon 19 Deletion, +1 more biomarker
drug
amivantamab, +3 more drugs
drug type
chemotherapy, +1 more type
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~21 mi. (Montréal, Canada, +247 more cities)
facility
Centre Hospitalier de l'Université de Montréal-Breast Cancer
biomarker
ER Positive, +1 more biomarker
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~21 mi. (Montréal, Canada, +176 more cities)
facility
McGill University Health Centre ( Site 3005), +1 more facility
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~21 mi. (Montréal, Canada, +89 more cities)
facility
Jewish General Hospital ( Site 0110)
biomarker
ER Positive, +2 more biomarkers
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~21 mi. (Montréal, Canada, +226 more cities)
facility
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0106)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type